❌

Normal view

Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study

Innovation (Camb). 2025 Aug 6;7(1):101076. doi: 10.1016/j.xinn.2025.101076. eCollection 2026 Jan 5.

ABSTRACT

Although circulating cell-free DNA (cfDNA) methylation has emerged as the mainstream approach in multi-cancer detection blood tests (MCDBTs), the potential of integrating proteins and mutations, to enhance its performance remains unclear. The PROMISE study (NCT04972201) was conducted to investigate the feasibility of a multi-omics integration strategy in MCDBTs across nine types of cancers in head and neck (excluding nasopharynx), esophagus, lung, stomach, liver, biliary tract, pancreas, colorectum, and ovary. Blood samples were prospectively collected from 1,706 participants (840 non-cancer; 866 cancer) and then randomly divided into training and validation sets. The complementarity between various omics were investigated, and specific omics features were carefully selected for further multimodal model construction. The methylation-based classifier outperformed both the mutation-based and protein-based classifiers. As 95.0% of cancer cases detected by the mutation-based classifier were simultaneously identified by the methylation-based classifier, while 14.0% of the protein-positive samples were missed, protein markers may provide complementary value to the methylation-based classifier. Compared with the methylation-based classifier, the multimodal classifier combining methylation and protein features exhibited an improved sensitivity of 75.1% (95% confidence interval [CI], 69.3%-80.3%) at the same specificity of 98.8% with the accuracy of top predicted origin (TPO1) of 73.1% (95% CI, 66.2%-79.2%). Notably, the TPO1 accuracy reached 100% in liver and ovarian cancers with negative results of the methylation-based classifier. Collectively, these data suggest that the integration of protein markers in the multimodal classifier can offer additional benefits to the methylation-based classifier, particularly in identifying liver and ovarian cancers.

PMID:41737326 | PMC:PMC12925926 | DOI:10.1016/j.xinn.2025.101076

A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer

npj Digital Medicine, Published online: 31 December 2025; doi:10.1038/s41746-025-02260-3

A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer

Reliable and Private Utility Signaling for Data Markets

arXiv:2511.07975v1 Announce Type: cross Abstract: The explosive growth of data has highlighted its critical role in driving economic growth through data marketplaces, which enable extensive data sharing and access to high-quality datasets. To support effective trading, signaling mechanisms provide participants with information about data products before transactions, enabling informed decisions and facilitating trading. However, due to the inherent free-duplication nature of data, commonly practiced signaling methods face a dilemma between privacy and reliability, undermining the effectiveness of signals in guiding decision-making. To address this, this paper explores the benefits and develops a non-TCP-based construction for a desirable signaling mechanism that simultaneously ensures privacy and reliability. We begin by formally defining the desirable utility signaling mechanism and proving its ability to prevent suboptimal decisions for both participants and facilitate informed data trading. To design a protocol to realize its functionality, we propose leveraging maliciously secure multi-party computation (MPC) to ensure the privacy and robustness of signal computation and introduce an MPC-based hash verification scheme to ensure input reliability. In multi-seller scenarios requiring fair data valuation, we further explore the design and optimization of the MPC-based KNN-Shapley method with improved efficiency. Rigorous experiments demonstrate the efficiency and practicality of our approach.
❌